Note: This seems to be a long list. The rationale is that I al focused on at least 20% gains and not just after bangers. My trading style is to compound those 10-15-20-30% earnings and roll all profit rather than waiting for runners everyday. If runners appear, then I’ll grab it as well. Each has his own style earning. $Damon Inc (DMN.US)$Can be my PM gapper. Low float EV stock. IPO las...
Trytosaveabit
:
As you know I’ve been waiting for this 510 clearance! I know most don’t like it! And admittedly the chart and volume are not looking good! Hehehe! But I really like, have like and continue to like MOVE! Hehehe! People don’t realize just how superior this is over the junk you can just buy on Amazon! Hehehe
$Adaptimmune Therapeutics (ADAP.US)$First Patient Treated With Adaptimmune's TECELRA(R) (Afamitresgene Autoleucel) newsfile· 2 mins ago Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma
$bluebird bio (BLUE.US)$FDA Investigating Serious Risk Of Hematologic Malignancy Following Skysona (Elivaldogene Autotemcel) Benzinga· 23 mins ago WARNING: HEMATOLOGIC MALIGNANCY Hematologic malignancy, including life-threatening cases of myelodysplastic syndrome, has occurred in patients treated with SKYSONA. Patients have been diagnosed between 14 months and 7.5 years after SKYSONA administ...
1
19
Report
Jaguar8
:
That is the really the accompanying risk of being ina clinical trial. This kind of adverse events is just troubling. I wonder how high their attrition rate is
Trytosaveabit
OP
Jaguar8
:
Yeah I know! It just sux! You have a drug that really helps just to find out later it can add to the already bad situation! Grrr
Today,$Amgen (AMGN.US)$announced the P2 trial results for MariTide, which only include the safety profile for the 420 mg dose escalation cohorts (cherry-picking at it's finest again). I suspect they chose not to present the full safety profile, given that the weight loss results for the 120 mg and 280 mg QM cohorts, in obese non-diabetics (without dose escalations), at week 16 in P2 are consistent with the P1 results (see slide 1). So, it is likely that the 120 mg and 280 mg QM (without dose...
$Damon Inc (DMN.US)$ Can be my PM gapper. Low float EV stock. IPO las...
newsfile· 2 mins ago
Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma
Benzinga· 23 mins ago
WARNING: HEMATOLOGIC MALIGNANCY Hematologic malignancy, including life-threatening cases of myelodysplastic syndrome, has occurred in patients treated with SKYSONA. Patients have been diagnosed between 14 months and 7.5 years after SKYSONA administ...
I suspect they chose not to present the full safety profile, given that the weight loss results for the 120 mg and 280 mg QM cohorts, in obese non-diabetics (without dose escalations), at week 16 in P2 are consistent with the P1 results (see slide 1). So, it is likely that the 120 mg and 280 mg QM (without dose...
MicroStrategy: +55% $MicroStrategy (MSTR.US)$
Coinbase: +51% Tesla: +35% $Coinbase (COIN.US)$
Bitcoin: +32% Banks: +14% $Bitcoin (BTC.CC)$
Small Caps: +7.3% $iShares Russell 2000 ETF (IWM.US)$
S&P 500: +4.2% $S&P 500 Index (.SPX.US)$
US Dollar: +3.7% $USD (USDindex.FX)$
US Bonds: +0.2%
---
International Stocks: -3.1%
Oil: -4.2%
Gold: -4.2%
Pfizer: -6.8% $Pfizer (PFE.US)$
China: -9.6%
Trump Media: -10% $Trump Media & Technology (DJT.US)$
Moderna: -21% $Moderna (MRNA.US)$